List of Inqovi drug patents
Inqovi is owned by Otsuka.
Inqovi contains Cedazuridine; Decitabine.
Inqovi has a total of 3 drug patents out of which 0 drug patents have expired.
Inqovi was authorised for market use on 07 July, 2020.
Inqovi is available in tablet;oral dosage forms.
Inqovi can be used as treatment of chronic myelomonocytic leukemia; treatment of myelodysplastic syndrome; method for inhibiting cytidine deaminase by administering cedazuridine; method for inhibiting degradation of a cda substrate by administering cedazuridine, method for inhibiting cytidine deaminase by administering cedazuridine; method for inhibiting degradation of a cda substrate by administering cedazuridine.
Drug patent challenges can be filed against Inqovi from 2024-07-07.
The generics of Inqovi are possible to be released after 22 August, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9567363 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(5 years from now) | |
| US8268800 | OTSUKA | Certain compounds, compositions and methods |
Aug, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618075 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 7, 2025 |
| Orphan Drug Exclusivity (ODE) | Jul 7, 2027 |
Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient
NCE-1 date: 2024-07-07
Market Authorisation Date: 07 July, 2020
Treatment: Method for inhibiting cytidine deaminase by administering cedazuridine; Method for inhibiting degradation of a cda substrate by administering cedazuridine; Treatment of chronic myelomonocytic leukemia...
Dosage: TABLET;ORAL
INQOVI family patents
6
United States
2
Spain
2
Japan
2
European Union
1
Israel
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Australia
1
Saudi Arabia
1
Hong Kong
1
Slovenia
1
Jordan
1
Costa Rica
1
Colombia
1
Croatia
1
Brazil
1
Guatemala
1
Portugal
1
Cyprus
1
Malaysia
1
Korea, Republic of
1
Poland
1
Taiwan, Province of China
1
RS
1
Ecuador
1
Nicaragua
1
China
1
Ukraine
1
EA
1
Canada
1
New Zealand
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic